{"version":"1.0","provider_name":"Basel Area Business &amp; Innovation","provider_url":"https:\/\/test.baselarea.swiss\/de\/","author_name":"J\u00e9r\u00e9mie Meyer","author_url":"https:\/\/test.baselarea.swiss\/de\/author\/jeremie\/","title":"BioMedPartners schliessen Wagniskapitalfonds","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"5jYN6udpU8\"><a href=\"https:\/\/test.baselarea.swiss\/de\/blog-post\/biomedpartners-schliessen-wagniskapitalfonds\/\">BioMedPartners schliessen Wagniskapitalfonds<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/test.baselarea.swiss\/de\/blog-post\/biomedpartners-schliessen-wagniskapitalfonds\/embed\/#?secret=5jYN6udpU8\" width=\"600\" height=\"338\" title=\"&#171;BioMedPartners schliessen Wagniskapitalfonds&#187; &#8212; Basel Area Business &amp; Innovation\" data-secret=\"5jYN6udpU8\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/* ]]> *\/\n<\/script>\n","thumbnail_url":"https:\/\/test.baselarea.swiss\/\/wp-content\/uploads\/2018\/03\/Biomed-portrait-gruppe.jpg.jpg","thumbnail_width":1000,"thumbnail_height":368,"description":"Das Basler Wagniskapitalunternehmen BioMedPartners hat den Fonds BioMedInvest III mit einem Kapital von 100 Millionen Franken geschlossen. Durch Investitionen in private Jungunternehmen soll nun der Schweizer Life Science Cluster weiterentwickelt werden."}